Diabetes mellitus type 1 screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]Anahita Deylamsalehi, M.D.[3]
Overview
Overview
According to the American Diabetic Association, screening for diabetes mellitus type 1 is not recommended. Nevertheless, there are some data proposing favorable effects within screened patients.
Screening
Screening
- According to the American diabetic association screening for diabetes mellitus type 1 is not recommended. However, one should consider referring relatives of those with type 1 diabetes for antibody testing for risk assessment in the setting of a clinical research. Higher-risk individuals may be tested, but only in the context of a clinical research setting.[1]
- Based on some studies, screening for diabetic patients has some favorable effects. The following table is a summary of screening effects based on 6 pediatric studies:[2][3][4][5][6][7]
| Study | Less DKA | Lower HbA1c | Lower insulin dose | Shorter hospitalization period |
|---|---|---|---|---|
| BABYDIAB and Munich | + | + | – | + |
| DiPiS | + | + | – | Not determined |
| TEDDY | + | + | + | Not determined |
| DAISY | + | + | + | + |
| DIPP | + | + | Not determined | Not determined |
*TEDDY (The Environmental Determinants of Diabetes in the Young) study reported higher c-peptide level at least within 12 months after diagnosis, which is related to better response to immunologic interventions.[5]
*DIPP (Finnish Type 1 diabetes Prediction and Prevention) reported lower rate of weight loss among patients who were screened for diabetes mellitus type 1[8]
References
References
- ↑ Invalid
<ref>tag; no text was provided for refs named:0 - ↑ Winkler C, Schober E, Ziegler AG, Holl RW (2012). “Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies”. Pediatr Diabetes. 13 (4): 308–13. doi:10.1111/j.1399-5448.2011.00829.x. PMID 22060727.
- ↑ Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C; et al. (2011). “Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up”. Diabetes Care. 34 (11): 2347–52. doi:10.2337/dc11-1026. PMC 3198296. PMID 21972409.
- ↑ Lundgren M, Sahlin Å, Svensson C, Carlsson A, Cedervall E, Jönsson B; et al. (2014). “Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up”. Pediatr Diabetes. 15 (7): 494–501. doi:10.1111/pedi.12151. PMC 4190091. PMID 24823816.
- ↑ 5.0 5.1 Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA; et al. (2017). “Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls”. Pediatr Diabetes. 18 (8): 794–802. doi:10.1111/pedi.12485. PMC 5529265. PMID 28127835.
- ↑ Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hämäläinen AM; et al. (2001). “Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort”. Diabetologia. 44 (3): 290–7. doi:10.1007/s001250051616. PMID 11317658.
- ↑ Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R (2018). “Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children”. Pediatr Diabetes. 19 (2): 314–319. doi:10.1111/pedi.12541. PMID 28544185.
- ↑ Narendran P (2019). “Screening for type 1 diabetes: are we nearly there yet?”. Diabetologia. 62 (1): 24–27. doi:10.1007/s00125-018-4774-0. PMC 6290651. PMID 30426167.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH